Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.

Benjamin Young,Kathleen Squires,Karen T. Tashima,Keith Henry,Stefan Schneider,Anthony LaMarca,Henry H. Zhao,Lisa L. Ross,Mark S. Shaefer

Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.

2015

Benjamin Young
Kathleen Squires
Karen T. Tashima
Keith Henry
Stefan Schneider
Anthony LaMarca
Henry H. Zhao
Lisa L. Ross
Mark S. Shaefer

To the EditorIn a previous issue of this journal [HIV Clinical Trials 2012;13(5):233–244], Squires and colleagues reported the 144-week results of a randomized, open-label, multicenter trial that u...

Keywords:

Virology
Renal function
Medicine
Abacavir/Lamivudine
Atazanavir
Atazanavir/ritonavir
antiretroviral therapy
human immunodeficiency virus
Diabetes mellitus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations